OAM
APLT

Oxford Asset Management’s Applied Therapeutics APLT Stock Holding History

Oxford Asset Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,033
Closed -$85.3K – 453
2024
Q3 		$85.3K Buy
+10,033
New +$59.1K 0.07% 279

Other funds holding APLT

VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Oxford Asset Management's APLT Position: Q4 2024 in Review

Oxford Asset Management sold out of Applied Therapeutics (APLT) in Q4 2024, closing a stake of 10,033 shares — an estimated $85.3K sold.

Oxford Asset Management first reported a position in APLT in Q3 2024 and held it in 1 quarter. The position peaked at $85.3K in Q3 2024. 119 funds tracked by Wall St. Rank hold APLT as of Q4 2024.

  • Oxford Asset Management reported no remaining Applied Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Oxford Asset Management sold 10,033 Applied Therapeutics shares in Q4 2024, an estimated $85.3K.
  • Oxford Asset Management first reported a position in Applied Therapeutics in Q3 2024 and held it in 1 quarter.
  • Oxford Asset Management's Applied Therapeutics position peaked at $85.3K in Q3 2024.
  • 119 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2024.

Based on Oxford Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.